Excreted by the kidneys. Total plasma dianabol before and after and kidney are respectively 1.2 ml / kg x min and 0.1 ml / kg x min. Terminal half-life after intravenous and subcutaneous administration are, respectively, an average of about 12 and 30 hours.

Indications. Prevention of premature ovulation in patients with controlled ovarian stimulation for oocyte and of assisted reproductive technologies.

Contraindications

  • Hypersensitivity to cetrorelix acetate, mannitol or other exogenous peptide hormones (drugs similar to drug Tsetrotid)
  • Pregnancy and lactation
  • postmenopausal
  • Renal or hepatic impairment

Pregnancy and lactation.
Tsetrotid is not intended for use during pregnancy and lactation.

Dosage and administration. Tsetrotid can be administered by a specialist gynecologist. To maximize the effectiveness of drug treatment Tsetrotid should carefully review these recommendations.

After the first 30 minutes of injection the patient must be under a doctor’s supervision, to be sure that there are no allergic or dianabol before and afterc reactions to the injection. All treatment conditions for this reaction must be available.

Tsetrotid 0.25 mg

The contents of 1 vial (0.25 mg cetrorelix) to be administered once a day every 24 hours in the morning or in the evening.

The introduction of the drug in the morning: Treatment Tsetrotidom should begin on day 5 or 6 of ovarian stimulation (approximately 96-120 hours after the start of stimulation) drug gonadotropin recombinant or isolated from urine, and continue throughout the gonadotropin stimulation period, including the day of the introduction of ovulatory dose of human chorionic gonadotropin .

The introduction of the drug in the evening: Treatment dianabol before and after should be initiated Tsetrotidom 5 days of ovarian stimulation (approximately 96-108 hours after the start of stimulation) drug gonadotropin recombinant or isolated from urine, and continue throughout the gonadotropin stimulation period, including the night preceding the day of the introduction of ovulatory dose hCG. Tsetrotid 3.0 mg

The contents of 1 vial (3.0 mg cetrorelix) should be administered on the 7th day of ovarian stimulation (approximately 132-144 hours after the start of stimulation) drug gonadotropin recombinant or isolated from urine.

After single administration of 3.0 mg cetrorelix drug effect continues for at least 4 days. If on day 5 after administration Tsetrotida 3.0 mg size of follicles does not allow you to assign ovulation induction should be added to 0.25 mg cetrorelix (Tsetrotid 0.25 mg) once daily, beginning 96 hours after administration of the drug Tsetrotid 3.0 mg and including the day of the introduction of ovulatory dose of hCG .

How to enter Tsetrotid 0.25 mg and 3.0 mg? (Patient information)

The first injection should be done by a specialist. After dianabol before and after obtaining the proper doctor’s instructions about the symptoms that may indicate the occurrence of an allergic reaction, of the consequences of such a reaction and the need for its treatment, the patient may self-administer Tsetrotid.

Tsetrotid for subcutaneous injection in the lower part of the anterior abdominal wall, preferably in the area around the navel. To avoid local irritation at repeated administration of the drug Tsetrotid injection site should be changed daily.

Tsetrotid should be dissolved only with the supplied solvent. During the dissolution of the vial should be gently shake. To avoid the formation of bubbles, should not be used vigorous agitation to accelerate dissolution.

Solution can not be used if it is opaque or contains undissolved particles.

From the vial into the syringe should be typed all of its contents. This will introduce cetrorelix dose at least 0.23 mg using 0.25 mg Tsetrotid drug and not less than 2.82 mg Tsetrotid drug using 3.0 mg.